GE HealthCare has unveiled its AI-powered ultrasound solution, Invenia Automated Breast Ultrasound (ABUS) Premium, to enhance breast cancer screening for patients with dense breast tissue.
Invenia ABUS Premium aims to improve early detection rates, which are crucial given that one-third of cancers in dense breasts can be masked in mammograms.
It enables the detection of cancer in dense breasts, offering clear and more detailed images to enhance the sensitivity in detecting invasive cancer alongside mammography.
The new 3D ultrasound system is engineered to handle high patient volumes while maintaining superior image quality.
Its Verisound AI tools help clinicians optimise efficiency, featuring Scan Quality Assessment for immediate evaluation and Auto Nipple Detection for consistent marker positioning.
The Fast Scan tool accelerates scan speed by up to 40%, while cSound Imageformer ensures high-resolution image quality.
The Invenia ABUS Viewer with AI Assistant enables effective reading, allowing physicians to quickly interpret patient exams, either in practice or remotely.
The AI tools enhance the ABUS 3D datasets review, for the detection and characterisation of breast lesions, improving clinical confidence and addressing staff shortages.
GE HealthCare comprehensive care ultrasound CEO Karley Yoder said: “Women with dense breasts often face poorer outcomes due to malignancies detected at later, more advanced stages.
“Invenia ABUS Premium equipped with AI has the potential to optimise clinicians’ screening capabilities, enabling them to detect even small, early-stage cancers with a high degree of confidence in women with dense breasts.
“Invenia ABUS Premium is designed to help deliver the best possible outcomes for patients while also prioritising the patient experience with features to improve scan speed and enhance comfort during an exam.”
The non-invasive design of the ABUS Premium enhances the patient experience, with a study indicating that all women would recommend the exam to a friend.
It also aims to reduce unnecessary biopsies by distinguishing malignant tumours, allowing for earlier intervention without exposing patients to radiation or contrast agents.
The Reverse Curve transducer adapts to the breast’s anatomy, and selectable compression levels offer personalised comfort.
Invenia ABUS Premium, which received Premarket Approval from the US Food and Drug Administration (FDA), will be launched in key countries throughout 2025.
Athena Medical founder and chief director Athina Vourtsis said: “The Invenia ABUS Premium is superior with its special AI features, which ensure the breast volume is captured and offer automatic nipple annotation, reducing scanning time and streamlining clinical workflow.
“The new Reverse Curve transducer makes the examination more patient-friendly, and it is much more comfortable.
“There has been great improvement in image quality with less shadowing, and the structures behind the area of the nipple are seen more clearly, providing radiologists with greater diagnostic confidence.”
